{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:22:07Z","timestamp":1778253727815,"version":"3.51.4"},"reference-count":28,"publisher":"Pharmaceutical Society of Japan","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2014]]},"DOI":"10.1248\/bpb.b13-00574","type":"journal-article","created":{"date-parts":[[2013,10,28]],"date-time":"2013-10-28T23:02:02Z","timestamp":1383001322000},"page":"67-73","source":"Crossref","is-referenced-by-count":35,"title":["Different Effects of Epigenetic Modifiers on the Cytotoxicity Induced by 5-Fluorouracil, Irinotecan or Oxaliplatin in Colon Cancer Cells"],"prefix":"10.1248","volume":"37","author":[{"given":"Mika","family":"Ikehata","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, Kobe Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Kobe Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Kobe Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Kobe Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Kobe Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seigo","family":"Iwakawa","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Kobe Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2011.08.001"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) K\u00f6hne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. <i>Oncologist<\/i>, 14, 478\u2013488 (2009).","DOI":"10.1634\/theoncologist.2008-0202"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1678"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Steensma DP. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes? <i>Best Pract. Res. Clin. Haematol.<\/i>, 25, 443\u2013451 (2012).","DOI":"10.1016\/j.beha.2012.10.007"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1722"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R151"},{"key":"7","unstructured":"7) Giannini G, Cabri W, Fattorusso C, Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. <i>Future Med. Chem.<\/i>, 4, 1439\u20131460 (2012)."},{"key":"8","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.12.7"},{"key":"9","unstructured":"9) Ishiguro M, Iida S, Uetake H, Morita S, Makino H, Kato K, Takagi Y, Enomoto M, Sugihara K. Effect of combined therapy with low-dose 5-aza-2\u2032-deoxycytidine and irinotecan on colon cancer cell line HCT-15. <i>Ann. Surg. Oncol.<\/i>, 14, 1752\u20131762 (2007)."},{"key":"10","unstructured":"10) Noguchi T, Tanimoto K, Shimokuni T, Ukon K, Tsujimoto H, Fukushima M, Noguchi T, Kawahara K, Hiyama K, Nishiyama M. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. <i>Clin. Cancer Res.<\/i>, 10, 7100\u20137107 (2004)."},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-9-10"},{"key":"12","unstructured":"12) Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. <i>Cancer Res.<\/i>, 63, 7291\u20137300 (2003)."},{"key":"13","unstructured":"13) Fazzone W, Wilson PM, Labonte MJ, Lenz HJ, Ladner RD. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. <i>Int. J. Cancer<\/i>, 125, 463\u2013473 (2009)."},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1495-6"},{"key":"15","unstructured":"15) Na YS, Kim SM, Jung KA, Yang SJ, Hong YS, Ryu MH, Ro S, Cho DH, Kim JC, Jin DH, Lee JS, Kim TW. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts. <i>Oncol. Rep.<\/i>, 24, 1509\u20131514 (2010)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) de la Chapelle A. Microsatellite instability. <i>N. Engl. J. Med.<\/i>, 349, 209\u2013210 (2003).","DOI":"10.1056\/NEJMp038099"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1469"},{"key":"18","unstructured":"18) Lind GE, Danielsen SA, Ahlquist T, Merok MA, Andresen K, Skotheim RI, Hektoen M, Rognum TO, Meling GI, Hoff G, Bretthauer M, Thiis-Evensen E, Nesbakken A, Lothe RA. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. <i>Mol. Cancer<\/i>, 10, 85\u201399 (2011)."},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.35.301"},{"key":"20","unstructured":"20) Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy\u2013chemotherapy: the concept of additivity. <i>Int. J. Radiat. Oncol. Biol. Phys.<\/i>, 5, 85\u201391 (1979)."},{"key":"21","unstructured":"21) Kano Y, Akutsu M, Tsunoda S, Izumi T, Mori K, Fujii H, Yazawa Y, Mano H, Furukawa Y. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines <i>in vitro.<\/i> <i>Cancer Chemother. Pharmacol.<\/i>, 54, 505\u2013513 (2004)."},{"key":"22","unstructured":"22) Shingu T, Yamada K, Hara N, Moritake K, Osago H, Terashima M, Uemura T, Yamasaki T, Tsuchiya M. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells. <i>Cancer Res.<\/i>, 63, 4044\u20134047 (2003)."},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.3.10"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB, Zahnow CA. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. <i>Cancer Cell<\/i>, 21, 430\u2013446 (2012).","DOI":"10.1016\/j.ccr.2011.12.029"},{"key":"25","unstructured":"25) Nguyen AN, Hollenbach PW, Richard N, Luna-Moran A, Brady H, Heise C, MacBech K. Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines. <i>Lung Cancer: Targets and Therapy<\/i>, 1, 119\u2013140 (2010)."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Morita S, Iida S, Kato K, Takagi Y, Uetake H, Sugihara K. The synergistic effect of 5-aza-2\u2032-deoxycytidine and 5-fluorouracil on drug-resistant tumors. <i>Oncology<\/i>, 71, 437\u2013445 (2006).","DOI":"10.1159\/000107110"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.10.033"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.07.017"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/37\/1\/37_b13-00574\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T05:32:08Z","timestamp":1615872728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/37\/1\/37_b13-00574\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b13-00574","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}